EGFR Mutant-selective Inhibitor PLB1004

Preferred Label : EGFR Mutant-selective Inhibitor PLB1004;

NCIt synonyms : Mutant-selective EGFR Inhibitor PLB1004;

NCIt definition : An orally bioavailable, mono-anilino-pyrimidine, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor PLB1004 targets, binds to and irreversibly inhibits the activity of various EGFR mutations, including exon 20 insertion (Ex20ins) activating mutations, the gatekeeper mutation T790M, ExDel19, and L858R. This prevents EGFR-mediated signaling, induces cell death and inhibits tumor growth in tumor cells expressing these EGFR mutations. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.;

Molecule name : PLB 1004; PLB-1004;

Details

Origin ID

C209347;

concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- EGFR Exon 19 Mutation [NCIt concept]
- EGFR Exon 20 Mutation [NCIt concept]
- EGFR NP_005219.2:p.L858R [NCIt concept]
- EGFR NP_005219.2:p.T790M [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients